about
Cognitive dysfunction and dementia in Parkinson diseaseMild cognitive impairment in Parkinson's disease.Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-upToxin-induced models of Parkinson's disease.Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria.Pattern of dopaminergic loss in the striatum of humans with MPTP induced parkinsonismThe cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?Striatal dopamine transporters correlate with simple reaction time in elderly subjectsCognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.MPTP-induced executive dysfunction is associated with altered prefrontal serotonergic functionDopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys.Cognitive impairment in nondemented Parkinson's disease.The current therapy of multiple sclerosis.Differential use of the betaL subunit of the type I interferon (IFN) receptor determines signaling specificity for IFNalpha2 and IFNbeta.Introductory remarks: immunosuppressive and immunomodulating drugs, where and how do they act?Mitoxantrone immunotherapy in multiple sclerosis.Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment.The MPTP Story.Loss of asymmetric spine synapses in prefrontal cortex of motor-asymptomatic, dopamine-depleted, cognitively impaired MPTP-treated monkeys.In vivo effects of mitoxantrone on the production of pro- and anti-inflammatory cytokines by peripheral blood mononuclear cells of secondary progressive multiple sclerosis patients.Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism. I. Effects of task complexity.Predictive parameters of mitoxantrone effectiveness in the treatment of multiple sclerosis.Severe delayed heart failure in three multiple sclerosis patients previously treated with mitoxantrone.Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis.Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.When did Ray Kennedy's Parkinson's disease begin?
P2860
Q22252885-CCED3C52-5F6E-4E00-9601-7D5B853C46DAQ27021220-FB79C0EB-10AC-482B-8B80-E96233339268Q28254413-0D5B531B-BAF4-42B1-9C4A-FCC1265996FBQ33844749-C3A57BDA-BA26-4112-98DD-9D2DCEFF1B37Q34064209-EFA42BDD-BC4E-4011-8F5C-4E44BCFAE854Q35455565-2EE4A66E-8AB2-48DC-8E7B-F11DBD200C24Q36407273-5501EC54-76D8-4E0A-858C-FDD458E6CAEBQ36469332-2EAF7CC7-9144-427D-B471-14E9B7CF1D3CQ36492310-E042044A-1DDA-4A41-97D5-B1424623C6AAQ36715856-65C6E2CB-8883-4C68-9C91-CD1E911C7A2BQ37186952-9FB5FCD8-F959-42BC-B525-7F62D6521CD7Q37968511-7244B4D5-26AF-4FB3-A7CA-C5C057E355D2Q40890050-8CE8274D-6DA8-44BC-98E8-75D164FB6F46Q41062121-32EEA20B-BDB3-428E-A270-4220CFCA1277Q41622065-982EAC3C-DF94-4C50-ABFF-EA74E4AF5643Q41622099-8F1AD964-83FC-4A9E-B3D6-B2BBDCF5A62CQ41622161-F7E31BDC-FA8D-483E-8262-01DC33BA3F4BQ41825283-45E81BA1-1F4A-42F9-8D42-3D4E9B6AE015Q42159942-11C55E3F-56D1-49A9-9E52-C644E042CB34Q42501446-CED20E17-AD30-4637-8DB7-DCF08BA453C7Q44729842-9C161320-5214-4367-A577-08553B49940CQ45028592-2C7B2889-738D-4257-B301-857B6061107FQ46441000-BAE13B5F-3297-4620-811C-B3D417DAFF23Q46641267-3C2FC770-5643-4541-95AB-3A61AF9072BCQ48276333-D7B32766-9F4A-4CEA-9F7D-857A4DF1418DQ52392414-C37DF12E-DFA4-47F6-BC73-C90CD8A6539A
P2860
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年学术文章
@wuu
1990年学术文章
@zh
1990年学术文章
@zh-cn
1990年学术文章
@zh-hans
1990年学术文章
@zh-my
1990年学术文章
@zh-sg
1990年學術文章
@yue
1990年學術文章
@zh-hant
name
Cognitive change following MPTP exposure.
@en
Cognitive change following MPTP exposure.
@nl
type
label
Cognitive change following MPTP exposure.
@en
Cognitive change following MPTP exposure.
@nl
prefLabel
Cognitive change following MPTP exposure.
@en
Cognitive change following MPTP exposure.
@nl
P2093
P356
P1433
P1476
Cognitive change following MPTP exposure.
@en
P2093
P304
P356
10.1212/WNL.40.2.261
P407
P577
1990-02-01T00:00:00Z